Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.36 HKD | -2.86% | +4.62% | -6.85% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.85% | 181M | |
-2.35% | 89.33B | |
+4.08% | 41.19B | |
-15.09% | 31.87B | |
+53.68% | 24.52B | |
-15.13% | 15.68B | |
-8.63% | 12.34B | |
-40.39% | 12.23B | |
+6.22% | 8.83B | |
-6.43% | 8.28B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug